Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets
Shares Up By 25% On Pipeline Progress
Executive Summary
Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.
You may also be interested in...
Amgen’s Olpasiran Maintains Competitive Profile In Lp(a) Class
The lipoprotein(a)-lowering antisense drug olpasiran reduced the cardiovascular disease risk factor Lp(a) by up to 101.1% relative to placebo. A Phase III trial will begin in December.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.